Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is This Biotech Stock Worth the Trouble?

TheMotleyFool

0 0

Is This Biotech Stock Worth the Trouble?Photo, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Biotech giant Biogen (NASDAQ: BIIB) has had its share of ups and downs in the past couple of years. Many of the headlines the company generated were related to the controversial approval of its Alzheimer's disease (AD) drug Aduhelm.

Biogen's stock has also been quite volatile during this period. Further, the issues related to Aduhelm aren't yet resolved, which may well be a problem for Biogen in the future. Should investors bother investing their hard-earned money in this company right now with all this going on?